Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with hodgkin lymphoma across jurisdictions

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 4, 2011, Pages 314-320

  Cerci, Juliano J ^a,d   Trindade, Evelinda ^a   Buccheri, Valeria ^a   Fanti, Stefano ^b   Coutinho, Artur M N ^a   Zanoni, Lucia ^b   Linardi, Camila C G ^a   Celli, Monica ^b   Delbeke, Dominique ^c   Pracchia, Luís F ^a   Pitela, Felipe A ^a   Soares Jr , José ^a   Zinzani, Pier Luigi ^b   Meneghetti, José C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d Division of PET CT   (Brazil)

Author keywords

Computed tomography; Cost effectiveness; FDG PET; Hodgkin lymphoma; Staging

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; VINBLASTINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ADOLESCENT; BIOPSY; BONE MARROW; BRAZIL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SCINTISCANNING;

ADOLESCENT; BIOPSY; BONE MARROW; BRAZIL; COST-BENEFIT ANALYSIS; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84555170809     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.06.006     Document Type: Article

References (24)

1. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31:1860-1.
2. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7:1630-6. (Pubitemid 19272832)
3. Urba WJ, Longo DL. Hodgkin's disease. N Engl J Med 1992; 326:678-87.
4. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus recommendations of the Imaging Subcommittee of the International Harmonization Project in Lymphoma. J Clin Oncol 2007; 10:571-8. (Pubitemid 350002965)
5. Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégi-cos. Departamento de Ciência e Tecnologia. Diretrizes metodológicas: elaboração de pareceres técnico-científicos/Ministério da Saúde, Secretaria de Ciência, Tec-nologia eInsumos Estratégicos, Departamento de Ciência e Tecnologia. 2nd ed. rev. e ampl. Brasília: Ministério da Saúde, 2009. (Série A. Normas e Manuais Técnicos)
6. Tarride JE, Blackhouse G, Bischof M, et al. Approaches for economic evaluations of health care technologies. J Appl Commun Res 2009; 6:307-16.
7. 18F]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) for accurate staging of Hodg-kin's disease. Ann Oncol 1998; 9:1117-22. (Pubitemid 28518151)
8. Spector N, Costa MA, Pulcheri W, et al. CMOPP/ABV yields good results in a public hospital population with Hodgkin disease inBrazil. Cancer 1993; 71:2823-7. (Pubitemid 23120062)
9. Hutchings M, Loft A, Hansen M, et al. Positron emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 2006; 91:482-9.
10. 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001; 86:266-73. (Pubitemid 32291064)
11. 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002; 81:20-5 (Pubitemid 36075491)
12. Menzel C, Döbert N, Mitrou P, et al. Positron emission tomography for the staging of Hodgkin's lymphoma\increasing the body of evidence in favor of the method. Acta Oncol 2002; 41:430-6. (Pubitemid 35222041)
13. Pracchia LF, Chaves AA, Cerci JJ, et al. Metabolic test with fluorine-18-fluorode-oxyglucose in staging and detection of residual tumor or recurrence in Hodgkin lymphoma. Clinics 2007; 62:121-6.
14. Cerci JJ, Pracchia LF, Soares-Junior J, et al. Positron emission tomography with 2-[18f]-fluoro-2-deoxy-d-glucose for initial staging of Hodgkin lymphoma: a single center experience in Brazil. Clinics 2009; 64:491-8.
15. Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005; 46:958-63. (Pubitemid 43733510)
16. Moulin-Romsee G, Hindié E, Moretti JL. (18) F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging 2010; 37:1095-105.
17. Kirby AM, Mikhaeel NG. The roleofFDG PET inthe managementoflymphoma: what is the evidence base? Nucl Med Commun 2007; 28:335-54.
18. 18F-FDG PET after 2 cycles of abvd predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med 2010; 51:1337-43.
19. Cerci JJ, Trindade E, Pracchia LF, et al. Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy. J Clin Oncol 2010; 28:1415-21.
20. Remonnay R, Morelle M, Pommier P, et al. Assessing short-term effects and costs at an early stage of innovation: the use of positron emission tomography on radiotherapy treatment decision making. Int J Technol Assess Health Care 2008; 24:212-20. (Pubitemid 351522735)
21. Bradbury I, Bonell E, Boynton J, et al. Health Technology Assessment Report 2: Positron emission tomography (PET) imaging in cancer management. Glasgow: Health Technology Board for Scotland; 2002. No. 1903961319.
22. 18F]fluorodeoxyglucose positron emission tomography in a healthy population: a preliminary report. J Clin Oncol 2009; 27:1767-73.
23. Klose T, Leidl R, Buchmann I, Brambs HJ, et al. Primary staging of lymphomas: cost-effectiveness of FDG-PET vs. computed tomography. Eur J Nucl Med 2000; 27:1457-64.
24. Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry [published correction appears in J Clin Oncol. 2008; 26:4229]. J Clin Oncol 2008; 26:2155-61.